Back to Peptides
CognitiveLow Risk

Semax

Also known as: ACTH(4-10) analogue, Meksidol

Half-life:
20–30 minutes (intranasal)

Administration Routes

intranasalsubcutaneous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Semax is believed to upregulate brain-derived neurotrophic factor (BDNF) and other neuroprotective factors, enhancing neuronal survival and synaptic plasticity. It modulates the dopaminergic and serotonergic systems, contributing to its reported effects on mood and focus. Its mechanism of action differs from classical stimulants — it does not act on adrenergic receptors and does not produce typical stimulant tolerance or dependence patterns.

Semax is a heptapeptide analogue of the adrenocorticotropic hormone fragment ACTH(4-10), developed in Russia. It has been approved for use in Russia and Ukraine for cognitive enhancement and neuroprotection. It is researched for nootropic, anxiolytic, and neuroprotective properties in the context of focus, stress resilience, and cognitive performance.

Primary Research Areas

  • cognitive
  • recovery

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Providers Offering Semax